RxDoctor Payments Data

M Nadir Alocozy, MD

Internal Medicine · Sacramento, CANPI 1821176538

Payments from drug & device makers

$4,024in general payments, 2019–2025

Across 195 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$686
  • Bayer$472
  • Novo Nordisk$372
  • Johnson & Johnson$346
  • AbbVie$333
  • GSK$295
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,024100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,024 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$200,151
Medicare patients
231
Services billed
1,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$96,619
JanuviaSitagliptin Phosphate39$44,808
EliquisApixaban39$39,542
TrulicityDulaglutide29$38,564
FarxigaDapagliflozin Propanediol56$30,462
XareltoRivaroxaban15$24,893
LinzessLinaclotide27$20,275
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$18,438
OxycontinOxycodone Hcl14$18,031
OzempicSemaglutide15$16,691
VascepaIcosapent Ethyl13$10,350
Breo ElliptaFluticasone/Vilanterol23$8,658
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,668
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen220$5,485
Atorvastatin Calcium499$5,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$126$96,61975 claims
MerckJanuvia$120$44,80839 claims
PfizerEliquis$126$39,54239 claims
Lilly USA, LLCTrulicity$259$38,56429 claims
AstraZenecaFarxiga, Breztri Aerosphere$686$37,13067 claims
GSKTrelegy Ellipta, Breo Ellipta$295$27,09653 claims
Johnson & JohnsonXarelto$346$24,89315 claims
AbbVieLinzess, Synthroid$333$21,90445 claims
Novo NordiskOzempic$372$16,69115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →